Drew M. Pardoll
M.D., Ph.D.
Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
👥Biography 个人简介
Drew Pardoll is a pioneer in cancer immunology who has made foundational contributions to understanding the PD-1/PD-L1 pathway and its role in tumor immune evasion. His laboratory discovered that PD-L1 expression by tumor cells directly inhibits T cell function, providing the mechanistic basis for PD-1/PD-L1 blockade therapy. Pardoll continues to lead efforts to understand and overcome immunotherapy resistance.
Drew Pardoll是癌症免疫学的先驱,在理解PD-1/PD-L1通路及其在肿瘤免疫逃逸中的作用方面做出了基础性贡献。他的实验室发现肿瘤细胞表达的PD-L1直接抑制T细胞功能,为PD-1/PD-L1阻断治疗提供了机制基础。Pardoll继续领导理解和克服免疫治疗耐药的努力。
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PD-L1 Discovery
Demonstrated that tumor PD-L1 expression mediates immune evasion through PD-1 engagement.
Combination Immunotherapy
Developed rationale for combining checkpoint inhibitors with other modalities.
Representative Works 代表性著作
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine (1999)
Original characterization of PD-L1 (B7-H1).
The blockade of immune checkpoints in cancer immunotherapy
Nature Reviews Cancer (2012)
Comprehensive review establishing checkpoint blockade paradigm.
📄Data Sources 数据来源
Last updated: 2026-03-04 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
Ira Mellman
Genentech / Roche
关注 Drew M. Pardoll 的研究动态
Follow Drew M. Pardoll's research updates
留下邮箱,当我们发布与 Drew M. Pardoll(Johns Hopkins University)相关的新研究或访谈时,我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment